3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Carcinoma, Transitional Cell
17
Neoplasms
6
Urologic Neoplasms
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Neoplasms by Site
3
Carcinoma in Situ
3
Carcinoma
3
Recurrence
2
Virus Diseases
1
Urothelial Carcinoma of the Bladder
1
Urothelial Carcinoma Ureter
1
Urogenital Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Recurrence, Local
1
Mycobacterium Infections
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Disease
1
Adenoviridae Infections
1
Interventions
padeliporfin
5
Nivolumab
5
Ipilimumab
4
Sunitinib
3
Specimen Handling
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Abiraterone Acetate
3
pembrolizumab
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
abiraterone
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Pluvicto
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
CTLA-4 Antigen
2
vinflunine
1
valrubicin
1
tislelizumab
1
temsirolimus
1
sipuleucel-T
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Mitomycin
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts